Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus
Identifieur interne : 000371 ( PascalFrancis/Corpus ); précédent : 000370; suivant : 000372Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus
Auteurs : LI LIU ; QING FANG ; FEI DENG ; HANZHONG WANG ; Christopher E. Yi ; LEI BA ; WENJIE YU ; Richard D. Lin ; TAISHENG LI ; ZHIHONG HU ; David D. Ho ; LINQI ZHANG ; ZHIWEI CHENSource :
- Journal of virology [ 0022-538X ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The severe acute respiratory syndrome (SARS) outbreak of 2002 and 2003 occurred as a result of zoonotic transmission. Coronavirus (CoV) found in naturally infected palm civet (civet-CoV) represents the closest genetic relative to SARS-CoV, but the degree and the determinants of cross-neutralization among these viruses remain to be investigated. Studies indicate that the receptor binding domain (RBD) of the SARS-CoV spike (S) glycoprotein contains major determinants for viral entry and neutralization. We aim to characterize the impact of natural mutations within the RBDs of civet-CoVs on viral entry and cross-neutralization. In this study, the S glycoprotein genes were recovered from naturally infected civets in central China (Hubei province), extending the geographic distribution of civet-CoV beyond the southeastern province of Guangdong. Moreover, pseudoviruses generated in our laboratory with four civet S genes, each with a distinct RBD, infected cells expressing human receptor angiotensin-converting enzyme 2, but with 90 to 95% less efficiency compared to that of SARS-CoV. These four civet S genes were also constructed as DNA vaccines to immunize mice. Immunized sera elicited against most civet S glycoproteins displayed potent neutralizing activities against autologous viruses but were much less efficient (50% inhibitory concentration, 20- to 40-fold) at neutralizing SARS-CoV and vice versa. Convalescence-phase sera from humans were similarly ineffective against the dominant civet pseudovirus. Our findings suggest that the design of SARS vaccine should consider not only preventing the reemergence of SARS-CoV but also providing cross-protection, thus interrupting zoonotic transmission of a group of genetically divergent civet CoVs of broad geographic origin.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 07-0245100 INIST |
---|---|
ET : | Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus |
AU : | LI LIU; QING FANG; FEI DENG; HANZHONG WANG; YI (Christopher E.); LEI BA; WENJIE YU; LIN (Richard D.); TAISHENG LI; ZHIHONG HU; HO (David D.); LINQI ZHANG; ZHIWEI CHEN |
AF : | Aaron Diamond AIDS Research Center, The Rockefeller University/New York, New York 100161/Etats-Unis (1 aut., 2 aut., 5 aut., 6 aut., 7 aut., 8 aut., 11 aut., 12 aut., 13 aut.); State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences/Hubei 430071/Chine (3 aut., 4 aut., 10 aut.); AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College/Beijing 100730/Chine (9 aut., 12 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2007; Vol. 81; No. 9; Pp. 4694-4700; Bibl. 31 ref. |
LA : | Anglais |
EA : | The severe acute respiratory syndrome (SARS) outbreak of 2002 and 2003 occurred as a result of zoonotic transmission. Coronavirus (CoV) found in naturally infected palm civet (civet-CoV) represents the closest genetic relative to SARS-CoV, but the degree and the determinants of cross-neutralization among these viruses remain to be investigated. Studies indicate that the receptor binding domain (RBD) of the SARS-CoV spike (S) glycoprotein contains major determinants for viral entry and neutralization. We aim to characterize the impact of natural mutations within the RBDs of civet-CoVs on viral entry and cross-neutralization. In this study, the S glycoprotein genes were recovered from naturally infected civets in central China (Hubei province), extending the geographic distribution of civet-CoV beyond the southeastern province of Guangdong. Moreover, pseudoviruses generated in our laboratory with four civet S genes, each with a distinct RBD, infected cells expressing human receptor angiotensin-converting enzyme 2, but with 90 to 95% less efficiency compared to that of SARS-CoV. These four civet S genes were also constructed as DNA vaccines to immunize mice. Immunized sera elicited against most civet S glycoproteins displayed potent neutralizing activities against autologous viruses but were much less efficient (50% inhibitory concentration, 20- to 40-fold) at neutralizing SARS-CoV and vice versa. Convalescence-phase sera from humans were similarly ineffective against the dominant civet pseudovirus. Our findings suggest that the design of SARS vaccine should consider not only preventing the reemergence of SARS-CoV but also providing cross-protection, thus interrupting zoonotic transmission of a group of genetically divergent civet CoVs of broad geographic origin. |
CC : | 002A05C10 |
FD : | Coronavirus; Mutation; Glycoprotéine; Réaction croisée; Neutralisation; Virologie; Syndrome respiratoire aigu sévère |
FG : | Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie |
ED : | Coronavirus; Mutation; Glycoprotein; Cross reaction; Neutralization; Virology; Severe acute respiratory syndrome |
EG : | Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection; Lung disease |
SD : | Coronavirus; Mutación; Glicoproteína; Reacción cruzada; Neutralización; Virología; Síndrome respiratorio agudo severo |
LO : | INIST-13592.354000149543340320 |
ID : | 07-0245100 |
Links to Exploration step
Pascal:07-0245100Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus</title>
<author><name sortKey="Li Liu" sort="Li Liu" uniqKey="Li Liu" last="Li Liu">LI LIU</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qing Fang" sort="Qing Fang" uniqKey="Qing Fang" last="Qing Fang">QING FANG</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fei Deng" sort="Fei Deng" uniqKey="Fei Deng" last="Fei Deng">FEI DENG</name>
<affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences</s1>
<s2>Hubei 430071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hanzhong Wang" sort="Hanzhong Wang" uniqKey="Hanzhong Wang" last="Hanzhong Wang">HANZHONG WANG</name>
<affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences</s1>
<s2>Hubei 430071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yi, Christopher E" sort="Yi, Christopher E" uniqKey="Yi C" first="Christopher E." last="Yi">Christopher E. Yi</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lei Ba" sort="Lei Ba" uniqKey="Lei Ba" last="Lei Ba">LEI BA</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wenjie Yu" sort="Wenjie Yu" uniqKey="Wenjie Yu" last="Wenjie Yu">WENJIE YU</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Richard D" sort="Lin, Richard D" uniqKey="Lin R" first="Richard D." last="Lin">Richard D. Lin</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Taisheng Li" sort="Taisheng Li" uniqKey="Taisheng Li" last="Taisheng Li">TAISHENG LI</name>
<affiliation><inist:fA14 i1="03"><s1>AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College</s1>
<s2>Beijing 100730</s2>
<s3>CHN</s3>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhihong Hu" sort="Zhihong Hu" uniqKey="Zhihong Hu" last="Zhihong Hu">ZHIHONG HU</name>
<affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences</s1>
<s2>Hubei 430071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D." last="Ho">David D. Ho</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Linqi Zhang" sort="Linqi Zhang" uniqKey="Linqi Zhang" last="Linqi Zhang">LINQI ZHANG</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College</s1>
<s2>Beijing 100730</s2>
<s3>CHN</s3>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhiwei Chen" sort="Zhiwei Chen" uniqKey="Zhiwei Chen" last="Zhiwei Chen">ZHIWEI CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0245100</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0245100 INIST</idno>
<idno type="RBID">Pascal:07-0245100</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000371</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus</title>
<author><name sortKey="Li Liu" sort="Li Liu" uniqKey="Li Liu" last="Li Liu">LI LIU</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qing Fang" sort="Qing Fang" uniqKey="Qing Fang" last="Qing Fang">QING FANG</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fei Deng" sort="Fei Deng" uniqKey="Fei Deng" last="Fei Deng">FEI DENG</name>
<affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences</s1>
<s2>Hubei 430071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hanzhong Wang" sort="Hanzhong Wang" uniqKey="Hanzhong Wang" last="Hanzhong Wang">HANZHONG WANG</name>
<affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences</s1>
<s2>Hubei 430071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yi, Christopher E" sort="Yi, Christopher E" uniqKey="Yi C" first="Christopher E." last="Yi">Christopher E. Yi</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lei Ba" sort="Lei Ba" uniqKey="Lei Ba" last="Lei Ba">LEI BA</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wenjie Yu" sort="Wenjie Yu" uniqKey="Wenjie Yu" last="Wenjie Yu">WENJIE YU</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Richard D" sort="Lin, Richard D" uniqKey="Lin R" first="Richard D." last="Lin">Richard D. Lin</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Taisheng Li" sort="Taisheng Li" uniqKey="Taisheng Li" last="Taisheng Li">TAISHENG LI</name>
<affiliation><inist:fA14 i1="03"><s1>AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College</s1>
<s2>Beijing 100730</s2>
<s3>CHN</s3>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhihong Hu" sort="Zhihong Hu" uniqKey="Zhihong Hu" last="Zhihong Hu">ZHIHONG HU</name>
<affiliation><inist:fA14 i1="02"><s1>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences</s1>
<s2>Hubei 430071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D." last="Ho">David D. Ho</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Linqi Zhang" sort="Linqi Zhang" uniqKey="Linqi Zhang" last="Linqi Zhang">LINQI ZHANG</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College</s1>
<s2>Beijing 100730</s2>
<s3>CHN</s3>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhiwei Chen" sort="Zhiwei Chen" uniqKey="Zhiwei Chen" last="Zhiwei Chen">ZHIWEI CHEN</name>
<affiliation><inist:fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Cross reaction</term>
<term>Glycoprotein</term>
<term>Mutation</term>
<term>Neutralization</term>
<term>Severe acute respiratory syndrome</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Mutation</term>
<term>Glycoprotéine</term>
<term>Réaction croisée</term>
<term>Neutralisation</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome (SARS) outbreak of 2002 and 2003 occurred as a result of zoonotic transmission. Coronavirus (CoV) found in naturally infected palm civet (civet-CoV) represents the closest genetic relative to SARS-CoV, but the degree and the determinants of cross-neutralization among these viruses remain to be investigated. Studies indicate that the receptor binding domain (RBD) of the SARS-CoV spike (S) glycoprotein contains major determinants for viral entry and neutralization. We aim to characterize the impact of natural mutations within the RBDs of civet-CoVs on viral entry and cross-neutralization. In this study, the S glycoprotein genes were recovered from naturally infected civets in central China (Hubei province), extending the geographic distribution of civet-CoV beyond the southeastern province of Guangdong. Moreover, pseudoviruses generated in our laboratory with four civet S genes, each with a distinct RBD, infected cells expressing human receptor angiotensin-converting enzyme 2, but with 90 to 95% less efficiency compared to that of SARS-CoV. These four civet S genes were also constructed as DNA vaccines to immunize mice. Immunized sera elicited against most civet S glycoproteins displayed potent neutralizing activities against autologous viruses but were much less efficient (50% inhibitory concentration, 20- to 40-fold) at neutralizing SARS-CoV and vice versa. Convalescence-phase sera from humans were similarly ineffective against the dominant civet pseudovirus. Our findings suggest that the design of SARS vaccine should consider not only preventing the reemergence of SARS-CoV but also providing cross-protection, thus interrupting zoonotic transmission of a group of genetically divergent civet CoVs of broad geographic origin.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-538X</s0>
</fA01>
<fA03 i2="1"><s0>J. virol.</s0>
</fA03>
<fA05><s2>81</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LI LIU</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>QING FANG</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FEI DENG</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HANZHONG WANG</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>YI (Christopher E.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LEI BA</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WENJIE YU</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LIN (Richard D.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TAISHENG LI</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ZHIHONG HU</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>HO (David D.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LINQI ZHANG</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>ZHIWEI CHEN</s1>
</fA11>
<fA14 i1="01"><s1>Aaron Diamond AIDS Research Center, The Rockefeller University</s1>
<s2>New York, New York 100161</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences</s1>
<s2>Hubei 430071</s2>
<s3>CHN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College</s1>
<s2>Beijing 100730</s2>
<s3>CHN</s3>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>4694-4700</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13592</s2>
<s5>354000149543340320</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0245100</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The severe acute respiratory syndrome (SARS) outbreak of 2002 and 2003 occurred as a result of zoonotic transmission. Coronavirus (CoV) found in naturally infected palm civet (civet-CoV) represents the closest genetic relative to SARS-CoV, but the degree and the determinants of cross-neutralization among these viruses remain to be investigated. Studies indicate that the receptor binding domain (RBD) of the SARS-CoV spike (S) glycoprotein contains major determinants for viral entry and neutralization. We aim to characterize the impact of natural mutations within the RBDs of civet-CoVs on viral entry and cross-neutralization. In this study, the S glycoprotein genes were recovered from naturally infected civets in central China (Hubei province), extending the geographic distribution of civet-CoV beyond the southeastern province of Guangdong. Moreover, pseudoviruses generated in our laboratory with four civet S genes, each with a distinct RBD, infected cells expressing human receptor angiotensin-converting enzyme 2, but with 90 to 95% less efficiency compared to that of SARS-CoV. These four civet S genes were also constructed as DNA vaccines to immunize mice. Immunized sera elicited against most civet S glycoproteins displayed potent neutralizing activities against autologous viruses but were much less efficient (50% inhibitory concentration, 20- to 40-fold) at neutralizing SARS-CoV and vice versa. Convalescence-phase sera from humans were similarly ineffective against the dominant civet pseudovirus. Our findings suggest that the design of SARS vaccine should consider not only preventing the reemergence of SARS-CoV but also providing cross-protection, thus interrupting zoonotic transmission of a group of genetically divergent civet CoVs of broad geographic origin.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Mutation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mutation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Mutación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Glycoprotéine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Glycoprotein</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Glicoproteína</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Réaction croisée</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cross reaction</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Reacción cruzada</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Neutralisation</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Neutralization</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Neutralización</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Virologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Virology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Virología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21><s1>162</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0245100 INIST</NO>
<ET>Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus</ET>
<AU>LI LIU; QING FANG; FEI DENG; HANZHONG WANG; YI (Christopher E.); LEI BA; WENJIE YU; LIN (Richard D.); TAISHENG LI; ZHIHONG HU; HO (David D.); LINQI ZHANG; ZHIWEI CHEN</AU>
<AF>Aaron Diamond AIDS Research Center, The Rockefeller University/New York, New York 100161/Etats-Unis (1 aut., 2 aut., 5 aut., 6 aut., 7 aut., 8 aut., 11 aut., 12 aut., 13 aut.); State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences/Hubei 430071/Chine (3 aut., 4 aut., 10 aut.); AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College/Beijing 100730/Chine (9 aut., 12 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2007; Vol. 81; No. 9; Pp. 4694-4700; Bibl. 31 ref.</SO>
<LA>Anglais</LA>
<EA>The severe acute respiratory syndrome (SARS) outbreak of 2002 and 2003 occurred as a result of zoonotic transmission. Coronavirus (CoV) found in naturally infected palm civet (civet-CoV) represents the closest genetic relative to SARS-CoV, but the degree and the determinants of cross-neutralization among these viruses remain to be investigated. Studies indicate that the receptor binding domain (RBD) of the SARS-CoV spike (S) glycoprotein contains major determinants for viral entry and neutralization. We aim to characterize the impact of natural mutations within the RBDs of civet-CoVs on viral entry and cross-neutralization. In this study, the S glycoprotein genes were recovered from naturally infected civets in central China (Hubei province), extending the geographic distribution of civet-CoV beyond the southeastern province of Guangdong. Moreover, pseudoviruses generated in our laboratory with four civet S genes, each with a distinct RBD, infected cells expressing human receptor angiotensin-converting enzyme 2, but with 90 to 95% less efficiency compared to that of SARS-CoV. These four civet S genes were also constructed as DNA vaccines to immunize mice. Immunized sera elicited against most civet S glycoproteins displayed potent neutralizing activities against autologous viruses but were much less efficient (50% inhibitory concentration, 20- to 40-fold) at neutralizing SARS-CoV and vice versa. Convalescence-phase sera from humans were similarly ineffective against the dominant civet pseudovirus. Our findings suggest that the design of SARS vaccine should consider not only preventing the reemergence of SARS-CoV but also providing cross-protection, thus interrupting zoonotic transmission of a group of genetically divergent civet CoVs of broad geographic origin.</EA>
<CC>002A05C10</CC>
<FD>Coronavirus; Mutation; Glycoprotéine; Réaction croisée; Neutralisation; Virologie; Syndrome respiratoire aigu sévère</FD>
<FG>Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie</FG>
<ED>Coronavirus; Mutation; Glycoprotein; Cross reaction; Neutralization; Virology; Severe acute respiratory syndrome</ED>
<EG>Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection; Lung disease</EG>
<SD>Coronavirus; Mutación; Glicoproteína; Reacción cruzada; Neutralización; Virología; Síndrome respiratorio agudo severo</SD>
<LO>INIST-13592.354000149543340320</LO>
<ID>07-0245100</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000371 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000371 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:07-0245100 |texte= Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus }}
This area was generated with Dilib version V0.6.33. |